Market Overview

UPDATE: Stifel Nicolaus Initiates Becton, Dickinson and Company at Hold; Acceleration Postponed

Share:
Related BDX
Earnings Scheduled For February 2, 2017
7 Biotech And Healthcare Picks For 2017 From Cantor Fitzgerald
Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Update (Seeking Alpha)

Stifel Nicolaus initiated coverage on Becton, Dickinson and Company (NYSE: BDX) with a Hold rating.

Stifel Nicolaus noted, "BD is a premier hospital supplies and diagnostic company with leading market shares in most of its major segments. Sales growth appears to have stabilized now in the ~4%-5% range ex-FX for two consecutive quarters -- following a sharp deceleration in the FY2009-2011 timeframe. But headwinds remain, given the ongoing difficulties of redicting improving global healthcare spending trends. As well, the lack of major visible new growth drivers, increased Diagnostic Systems division competition, and ongoing uncertainties surrounding government funding for the Biosciences division remain challenging."

Becton, Dickinson and Company closed at $75.59 on Monday.

Latest Ratings for BDX

DateFirmActionFromTo
Jan 2017Raymond JamesDowngradesStrong BuyOutperform
Jan 2017JP MorganDowngradesOverweightNeutral
Sep 2016CitigroupDowngradesNeutralSell

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!